COVID-19 Booster Yields Responses After Failure of Initial Vaccine Doses in Prior HCT or CAR T Recipients - Episode 4

Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients

Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.

EP. 1: Dr. Abid on the Efficacy of a Third COVID-19 Vaccine Dose After Hematopoietic Cell
EP. 2: Third Dose of COVID-19 Vaccine Improves Response in Patients Treated with HCT and Cellular Therapies
EP. 3: COVID-19 Booster Yields Responses After Failure of Initial Vaccine Doses in Prior HCT or CAR T-Cell Therapy Recipients
Now Viewing
EP. 4: Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients

Welcome to OncLive On Air®! I’m your host today, Kristi Rosa.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by, we had the pleasure of speaking with Muhammad Abid, MD, MRCP, FRCPE, an assistant professor of medicine in the Divisions of Hematology/Oncology & Infectious Disease at the Medical College of Wisconsin.

In a review paper, published in Cancer Cell, Abid and colleagues took a closer look at determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.

Among patients who did not undergo seroconversion after the primary administration series of an mRNA-based SARS-CoV-2 vaccine, 59% were found to develop antibodies following the third dose. Seroconversion rates were 63% in those who received autologous transplant, 58% in those who underwent allogeneic transplant, 40% in those administered CAR T-cell therapy, and 67% in those who were given BiTEs.

In our exclusive interview, Abid further discussed the study and its results, and drove home the message that a third vaccine dose should be considered for these patients, as often as possible.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.